Kynurenine [73] and indoxyl sulfate [74] could exacerbate osteoporosis by decreasing bone strength and affecting osteoclastogenesis through AhR-associated mechanisms, respectively, the inhibition of which might provide new opportunities for the treatment of osteoporosis in CKD. The gene discussed is AHR; the disease is chronic kidney disease.